Skip to Main Content

A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer

Conditions

Corpus Uteri

Phase II

What is the purpose of this trial?

The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).

  • Trial with
    Yale Cancer Center
  • Start Date
    06/22/2020
  • End Date
    10/30/2023
Trial Image

For more information about this study, contact:

Martha Luther

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/24/2020
  • Study HIC
    #2000023841